IGF1 and atypical Rett syndrome: From a therapeutic perspective, IGF-1 pathway modulation shows the most advanced translational progress, particularly in Rett syndrome and Phelan–McDermid syndrome, where early-phase trials have reported improvements in selected behavioral and electrophysiological endpoints, although a broad efficacy in ASD is unproven and the long-term benefit–risk profile remains unclear.